fbpx
Sponsored Clinical and Research Opportunities2022-08-24T06:48:27-04:00

Sponsored Clinical and Research Opportunities for Patients

Below you will find sponsored clinical trial and research opportunities available to the pulmonary hypertension community.  For a complete list of clinical trials, visit PHA Clinical Trial Finder or ClinicalTrials.gov. To learn more about research and clinical trials, visit PHAssociation.org/Research.

Paid Research Study Seeks BREEZE (NCT03950739) Clinical Trial Participants

Population: Adult patients with PAH who participated in the BREEZE clinical trial.

Start Date: August 23, 2022

End Date: September 30, 2022

Phase: IV

Institution: RTI Health Solutions, United Therapeutics

International not-for-profit research organization, RTI Health Solutions (RTI-HS), in partnership with United Therapeutics is conducting interviews to gather patient feedback from individuals who participated in the BREEZE clinical trial.

This new qualitative research study consists of gathering feedback on a questionnaire called “Preference Questionnaire for Inhaled Treprostinil Devices (PQ-ITD) from individuals who previously participated in the BREEZE clinical trial (NCT03950739) or who are currently participating in the optional extension phase of the trial.

The study involves:
• Participating in a web-based (i.e., Zoom) 60-minute interview. The interview will be conducted by two researchers from RTI-HS. During the interview, you will be asked to review the content, wording and response options included in the PQ-ITD, as well as some brief questions about your experiences with the COVID-19 pandemic and how it has impacted your PAH.
• If you are currently participating in the BREEZE optional extension phase and/or still using the Tyvaso dry powder inhaler, you will be invited to take part in an extended 30-minute interview to discuss your experiences using the Tyvaso dry powder inhaler.

The interview will be arranged at a time and date convenient to you.
Each participant will receive $75 for taking part in this study. Participants who take part in the extended interview will receive an additional $25.
The information you give will help ensure that the final questionnaire includes issues important to patients regarding inhaler preference. Any information collected as part of this study will be kept confidential.

If you are interested in taking part in this research study or discussing the study in more detail, please contact Ross Morrison. If you decide that you wish to participate, the research team will schedule a brief call to check whether you meet the criteria for participation in this research study.

These opportunities are not affiliated with, endorsed by, or supported by the Pulmonary Hypertension Association or its affiliates (collectively, “PHA”).  Participation in these opportunities do not affect your relationship with PHA or its entities. Information obtained by companies or researchers is not shared with PHA or any of its PH-accredited Care Center programs.

Title